N’envoyez pas un CV générique — générez un CV et une lettre de motivation adaptés à ce poste précis.
Alfasigma is a privately held global healthcare company with a strong focus on GI health, expanding its presence in France. We seek a Medical Advisor on a fixed-term assignment (Sept 2026–May 2027) reporting to the Medical Director to lead medical launch activities for a new indication in France.
You will drive Phase IV evidence, engage external experts, develop medical content, and ensure scientific readiness across cross-functional teams while maintaining the highest standards of ethics and
Select how often (in days) to receive an alert:
Alfasigma is a privately held global healthcare company founded over 75 years ago in Italy, where it remains headquartered today in Bologna and Milan. The Group operates in over 100 markets spanning Europe, North and South America, Asia, and Africa.
Over three years ago, we embarked on a transformative journey to become a truly global innovative healthcare company with a leading focus on Gastrointestinal (GI) health. We have experienced remarkable growth, nearly doubled our revenues, expanding geographically, and integrating several key acquisitions. We have also evolved our portfolio, expanded into rare and specialty segments, and strengthened our pipeline and people's capabilities.
But our journey is far from complete! In fact, this is just the beginning of a bold new chapter in Alfasigma's history. We are committed to advancing innovation and leveraging our deep expertise to provide better health and a better quality of life for patients and consumers worldwide and expand our reach across diverse markets.
The Medical Advisor will play a pivotal role in supporting the successful launch of a new indication in France during a fixed-term assignment (September-October 2026 to May 2027) and will report to the Medical Director.
Among other responsibilities, the Medical Advisor will lead key medical launch activities, drive scientific engagement with external stakeholders, support evidence generation and communication, and ensure medical readiness across the organization. Working closely with cross-functional teams, the role will help shape launch strategy and execution, contributing to the successful introduction of the new indication in the French market while upholding the highest standards of scientific excellence, ethics, and compliance.
Lead and support Phase IV evidence generation activities, ensuring post-launch medical initiatives contribute to data generation, clinical adoption, and long-term indication success.
Drive the planning, implementation, and oversight of Phase IV studies and other post-launch evidence generation activities, collaborating closely with investigators and internal stakeholders to support the successful adoption of the new indication.
At Alfasigma, we foster a culture where the courage to innovate is key to our success.
We offer a competitive salary, comprehensive benefits, and extensive opportunities for professional growth and development.
Our commitment to people and patients is at the heart of everything we do. We value diversity and welcome individuals with unique perspectives and experiences. We believe that open-mindedness, collaboration, and a shared passion for innovation are essential to achieving meaningful progress.
Join Alfasigma and become part of a forward-thinking team dedicated to shaping the future of the pharmaceutical industry.